by The global Hospital Surgical Disinfectant market size is expected to be worth around US$ 658.54 million by 2030, according to a new report by Vision Research Reports.
The global Hospital Surgical Disinfectant market size was valued at US$ 430.83 million in 2020 and is anticipated to grow at a CAGR of 8.0% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39045
Growth Factors
The increasing prevalence of surgical site infections and hospital-acquired infections (HAIs) is a key driving factor for the market. Moreover, the recent outbreak of the COVID-19 pandemic has led to the significant demand for surgical disinfectants and is expected to reach new frontiers in the forthcoming months. Major players operating in the market are developing hospital surgical disinfectants that are effective against COVID-19. For instance, BD introduced fully sterile isopropyl alcohol and povidone-iodine single-use antiseptic skin preparation in the U.S., thus positively supporting the market growth.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 658.54 million by 2030 |
| Growth Rate | CAGR of 8.0% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | 3M; Ecolab; BD; Sage Products LLC; B. Braun Melsungen AG; Johnson & Johnson; Kimberly-Clark Corporation; Cardinal Health; The Clorox Company; Schulke & Mayr GmbH |
By Product Analysis
The chlorhexidine segment dominated the market in 2020 with a share of over 25.0% owing to the increased usage of formulation for pre-injection and pre-operative skin preparation. In addition, the growing demand for chlorhexidine-based products to be used in combination with other formulations, such as iodine and alcohol, is fueling the segment growth.
Chlorhexidine is also expected to expand at the highest CAGR from 2021 to 2030 owing to the growing awareness and increasing applications of surgical disinfectants in pre-operation and pre-injection skin preparation during surgical procedures.
CHG has a broad spectrum in antimicrobial activity and has very rare side effects and persistent antimicrobial activity. It is used in different concentrations of 0.9%, 2%, and 4%.
This increase in awareness regarding chlorhexidine benefits for hygiene and a surge in the number of surgical procedures are the other key factors that are projected to drive the segment during the forecast period.
By End-use Analysis
The hospitals segment dominated the overall market in terms of revenue in 2020 with a share of over 45.0%. The rising prevalence of infections and an increasing number of surgical procedures are some of the key factors driving the hospital segment.
The usage of proper surgical disinfectants is essential as it helps in preventing the transmission of infections. According to a survey, maximum hospitals and healthcare centers are in Asia Pacific, thereby leading to market growth.
increasing healthcare expenditure in developed and developing countries might increase the number of hospitals owing to which demand for surgical hospital disinfectants is also expected to increase, thereby contributing to the segment growth.
The ambulatory surgical centers segment is expected to witness lucrative growth over the forecast period. Increasing awareness regarding one-day surgeries is a major factor behind the segment growth.
Owing to the increasing cost of medical procedures, people in many countries are opting for ASCs as the treatment cost in these centers is less as compared to hospitals. Increasing use of advanced surgical equipment in ASCs is attracting people to seek medical treatment at these centers.
Growing different types of procedures with reimbursement opportunities is further anticipated to drive the segment. These factors are expected to drive the adoption of surgical disinfectants in ASCs, thereby boosting the segment growth over the forecast period.
By Regional Analysis
Asia Pacific dominated the market with a share of over 25.0% in 2020 and is expected to grow at the fastest rate from 2021 to 2030. This can be attributed to the factors such as the high prevalence of hospital-acquired infections and development in healthcare infrastructure, which boost the adoption of hospital surgical disinfectants.
National Medical Products Administration (NMPA), which is the Chinese regulatory authority, announced that they will accelerate the registration of those medical disinfectants that meet relevant standards in the U.S., Japan, and the EU. Hence, these factors are expected to propel the growth of the market over the forecast period. Moreover, increasing diseases and surgeries in the region may further boost market growth.
Increasing healthcare expenditure by the public and private sectors is one of the major driving factors of the market. Such a scenario is anticipated to encourage several international and local companies to enter the regional market, thereby augmenting the growth.
Key Players
- 3M
- Ecolab
- BD
- Sage Products LLC
- B. Braun Melsungen AG
- Johnson & Johnson
- Kimberly-Clark Corporation
- Cardinal Health
- The Clorox Company
- Schülke & Mayr GmbH
Market Segmentation
- By Product
- Alcohols
- Chlorhexidine
- Povidone-iodine
- Octenidine
- Hydrogen Peroxide
- Others
- By End-use
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Hospital Surgical Disinfectant Market, By Product
7.1. Hospital Surgical Disinfectant Market, by Product, 2021-2030
7.1.1. Alcohols
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Chlorhexidine
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Povidone-iodine
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Octenidine
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Hydrogen Peroxide
7.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Hospital Surgical Disinfectant Market, By End-use
8.1. Hospital Surgical Disinfectant Market, by End-use, 2021-2030
8.1.1. Hospitals
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Clinics
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Ambulatory Surgical Centers
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Hospital Surgical Disinfectant Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Product (2017-2030)
9.1.2. Market Revenue and Forecast, by End-use (2017-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Product (2017-2030)
9.1.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
9.1.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Product (2017-2030)
9.2.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Product (2017-2030)
9.2.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
9.2.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
9.2.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
9.2.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Product (2017-2030)
9.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Product (2017-2030)
9.3.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
9.3.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
9.3.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
9.3.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Product (2017-2030)
9.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Product (2017-2030)
9.4.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
9.4.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
9.4.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
9.4.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Product (2017-2030)
9.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Product (2017-2030)
9.5.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
9.5.4.2. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 10. Company Profiles
10.1. 3M
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Ecolab
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. BD
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Sage Products LLC
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. B. Braun Melsungen AG
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Johnson & Johnson
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Kimberly-Clark Corporation
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Cardinal Health
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. The Clorox Company
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Schülke & Mayr GmbH
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39045
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
